Clinical Trials Directory

Trials / Terminated

TerminatedNCT02258854

An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data

An Open-Label, Non-Randomized, Single-Arm, Rollover Study to Continue Dosing of Gevokizumab in Subjects With Non Infectious Intermediate-, Posterior-, or Pan-Uveitis Patients Who Each Successfully Completed Either the X052130/CL3-78989-005 (EYEGUARD™-A) or the X052131/CL3-78989-006 (EYEGUARD™-C) Study or Who Have Controlled Ocular Inflammation After Receiving Study Drug in Study X052133 (EYEGUARD™-US)

Status
Terminated
Phase
Phase 3
Study type
Interventional
Enrollment
69 (actual)
Sponsor
XOMA (US) LLC · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to provide continued dosing of gevokizumab in order to obtain and assess long-term gevokizumab safety data.

Conditions

Interventions

TypeNameDescription
DRUGDose 2 gevokizumabSolution for subcutaneous injection

Timeline

Start date
2014-03-01
Primary completion
2017-10-01
Completion
2017-12-01
First posted
2014-10-08
Last updated
2015-10-16

Locations

33 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT02258854. Inclusion in this directory is not an endorsement.